Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Cells and Metastasis, Cancer Genomics and Diagnostics, Breast Cancer Treatment Studies, and HER2/EGFR in Cancer Research.
Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Discovery of a sushi domain-containing protein 2-positive phenotype in circulating tumor cells of metastatic breast cancer patients
Cluster-based human-in-the-loop strategy for improving machine learning-based circulating tumor cell detection in liquid biopsy
Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells—The DETECT III Clinical Trial
Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells
Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma
Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary
HER2(-Low) Expression on Circulating Tumor Cells and Corresponding Metastatic Tissue in Metastatic Breast Cancer
Tissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22
PSMA‐heterogeneity in metastatic castration‐resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy
EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma
Detection and Isolation of Circulating Tumor Cells from Breast Cancer Patients Using CUB Domain-Containing Protein 1
Abstract PD18-07: Omission of chemotherapy in the treatment of HER2-positive and hormone-receptor positive metastatic breast cancer – interim results from the randomized phase 3 DETECT V trial
Relationship of Ki-67 index in biopsies of metastatic breast cancer tissue and circulating tumor cells (CTCs) at the time of biopsy collection
Protocol of the <scp>IntenSify‐Trial</scp>: An open‐label phase I trial of the <scp>CYP3A</scp> inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy
174P Frequency and prognostic value of circulating tumor cells in cancer of unknown primary
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation
Abstract 3374: Large-scale single-cell whole transcriptomic analyses reveal distinct malignant phenotypes of CTCs from NSCLC patients
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
Abstract GS4-08: Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data
Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity
Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID
High-resolution analysis of Merkel Cell Polyomavirus in Merkel Cell Carcinoma reveals distinct integration patterns and suggests NHEJ and MMBIR as underlying mechanisms
HER2-targeted therapy influences CTC status in metastatic breast cancer
Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay
High-resolution analysis of Merkel Cell Polyomavirus in Merkel Cell Carcinoma reveals distinct integration patterns and suggests NHEJ and MMBIR as underlying mechanisms
The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer
DETECT V/CHEVENDO - duale HER2-zielgerichteten Therapie mit Trastuzumab und Pertuzumab plus Ribociclib in Kombination mit Chemotherapie oder endokriner Therapie bei Patientinnen mit HER2-positivem und hormonrezeptor-positivem metastasierten Mammakarzinom